story of the week
Advantages of Metronomic Chemotherapy in Metastatic TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Breast Cancer Res Treat 2021 Sep 21;[EPub Ahead of Print], ME Cazzaniga, I Vallini, E Montagna, D Amoroso, R Berardi, A Butera, K Cagossi, L Cavanna, M Ciccarese, S Cinieri, E Cretella, E De Conciliis, A Febbraro, F Ferraù, A Ferzi, A Baldelli, A Fontana, AR Gambaro, O Garrone, V Gebbia, D Generali, L Gianni, F Giovanardi, A Grassadonia, V Leonardi, P Marchetti, S Sarti, A Musolino, M Nicolini, C Putzu, F Riccardi, D Santini, S Saracchini, MG Sarobba, MG Schintu, G Scognamiglio, P Spadaro, C Taverniti, D Toniolo, P Tralongo, A Turletti, R Valenza, MR Valerio, P Vici, P Di Mauro, V Cogliati, S Capici, L Clivio, V TorriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.